BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33605429)

  • 1. Flow cytometry reveals the nuances of clonal haematopoiesis.
    Hasserjian RP
    Br J Haematol; 2021 Mar; 192(6):949-950. PubMed ID: 33605429
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Flow Cytometry Analysis in the Setting of Chronic Myeloid Neoplasms and Clonal Hematopoiesis.
    El Hussein S; Loghavi S
    Clin Lab Med; 2023 Sep; 43(3):411-426. PubMed ID: 37481320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Non-Malignant Clonal Hematopoiesis.
    Dillon LW; Ghannam J; Nosiri C; Gui G; Goswami M; Calvo KR; Lindblad KE; Oetjen KA; Wilkerson MD; Soltis AR; Sukumar G; Dalgard CL; Thompson J; Valdez J; DeStefano CB; Lai C; Sciambi A; Durruthy-Durruthy R; Llanso A; Gulati S; Wang S; Ooi A; Dagur PK; McCoy JP; Burr P; Li Y; Hourigan CS
    Blood Cancer Discov; 2021 Jul; 2(4):319-325. PubMed ID: 34258102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia.
    Hasserjian RP; Steensma DP; Graubert TA; Ebert BL
    Blood; 2020 May; 135(20):1729-1738. PubMed ID: 32232484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    Jongen-Lavrencic M; Grob T; Hanekamp D; Kavelaars FG; Al Hinai A; Zeilemaker A; Erpelinck-Verschueren CAJ; Gradowska PL; Meijer R; Cloos J; Biemond BJ; Graux C; van Marwijk Kooy M; Manz MG; Pabst T; Passweg JR; Havelange V; Ossenkoppele GJ; Sanders MA; Schuurhuis GJ; Löwenberg B; Valk PJM
    N Engl J Med; 2018 Mar; 378(13):1189-1199. PubMed ID: 29601269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia?
    Xu J; Jorgensen JL; Wang SA
    Clin Lab Med; 2017 Dec; 37(4):787-802. PubMed ID: 29128069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute Myeloid Leukemia Immunophenotyping by Flow Cytometric Analysis.
    Chen X; Cherian S
    Clin Lab Med; 2017 Dec; 37(4):753-769. PubMed ID: 29128067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor heterogeneity makes AML a "moving target" for detection of residual disease.
    Zeijlemaker W; Gratama JW; Schuurhuis GJ
    Cytometry B Clin Cytom; 2014 Jan; 86(1):3-14. PubMed ID: 24151248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    Mauvieux L; Miguet L; Fornecker L
    N Engl J Med; 2018 Jun; 378(25):2442-3. PubMed ID: 29926700
    [No Abstract]   [Full Text] [Related]  

  • 10. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    Ulrich BC
    N Engl J Med; 2018 Jun; 378(25):2442. PubMed ID: 29926698
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach.
    Wood BL
    Curr Protoc Cytom; 2020 Jun; 93(1):e73. PubMed ID: 32311834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    Löwenberg B; Valk PJM
    N Engl J Med; 2018 Jun; 378(25):2443. PubMed ID: 29924951
    [No Abstract]   [Full Text] [Related]  

  • 13. Monitoring of minimal residual disease in acute myeloid leukemia: methods and best applications.
    Jorgensen JL; Chen SS
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S49-53. PubMed ID: 22035748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beware clonal haematopoiesis following chronic lymphocytic leukaemia treatment.
    Claxton DF
    Br J Haematol; 2022 Jul; 198(1):9-10. PubMed ID: 35362550
    [No Abstract]   [Full Text] [Related]  

  • 15. Clonal Hematopoiesis after Induction Chemotherapy for Acute Myeloid Leukemia.
    Steensma DP; Ebert BL
    N Engl J Med; 2018 Mar; 378(13):1244-1245. PubMed ID: 29590545
    [No Abstract]   [Full Text] [Related]  

  • 16. [Advances in minimal residual disease detection with flow cytometry in childhood acute myeloid leukemia].
    Feng JH; Xu XJ; Tang YM
    Zhonghua Er Ke Za Zhi; 2013 Mar; 51(3):231-4. PubMed ID: 23751588
    [No Abstract]   [Full Text] [Related]  

  • 17. A refined approach to detect and measure minimal residual disease in childhood acute myeloid leukemia by flow cytometry.
    Capolunghi F; Capponi C; De Stefani B; Luciani M; Locatelli F; Muraca M; Carsetti R
    Am J Hematol; 2014 Mar; 89(3):343-4. PubMed ID: 24265183
    [No Abstract]   [Full Text] [Related]  

  • 18. Combining flow cytometry and
    Guolo F; Minetto P; Clavio M; Miglino M; Galaverna F; Raiola AM; Di Grazia C; Colombo N; Pozzi S; Ibatici A; Bagnasco S; Guardo D; Kunkl A; Ballerini F; Ghiggi C; Lemoli RM; Gobbi M; Bacigalupo A
    Haematologica; 2017 Sep; 102(9):e348-e351. PubMed ID: 28495917
    [No Abstract]   [Full Text] [Related]  

  • 19. [Detection of minimal residual disease in leukemia using flow cytometry].
    Muroi K
    Rinsho Ketsueki; 2008 Jun; 49(6):397-407. PubMed ID: 18646607
    [No Abstract]   [Full Text] [Related]  

  • 20. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
    Fuda F; Chen W
    Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.